Randomized controlled trials in vasculitis associated with anti-neutrophil cytoplasmic antibodies

Current Opinion in Rheumatology

Volumn 17, Issue 3, 2005, Pages 257-264

  Goek, Oemer N ^a   Stone, John H ^b,c  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b JOHNS HOPKINS BAYVIEW MEDICAL CENTER   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Anti neutrophil cytoplasmic antibodies; Azathioprine; Cyclophosphamide; Etanercept; Vasculitis

Indexed keywords

AZATHIOPRINE; CYCLOPHOSPHAMIDE; ETANERCEPT; METHOTREXATE; METHYLPREDNISOLONE; NEUTROPHIL CYTOPLASMIC ANTIBODY; PREDNISOLONE;

CLINICAL TRIAL; DISEASE SEVERITY; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; FOLLOW UP; HUMAN; LEUKOPENIA; LIVER DISEASE; MICROSCOPIC POLYANGIITIS; PNEUMOCYSTOSIS; PRIORITY JOURNAL; REMISSION; REVIEW; SIDE EFFECT; WEGENER GRANULOMATOSIS;

ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC; AZATHIOPRINE; CYCLOPHOSPHAMIDE; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; METHOTREXATE; RANDOMIZED CONTROLLED TRIALS; RECEPTORS, TUMOR NECROSIS FACTOR; TREATMENT OUTCOME; WEGENER GRANULOMATOSIS;

EID: 18144382238     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.bor.0000160777.28259.c2     Document Type: Review

References (8)

1. Jayne D, Rasmussen N, Andrassy K, et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med 2003; 349:36-44.
2. deGroot K, Rasmussen N, Bacon PA, et al. Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic ANCA-associated vasculitis. Arthritis Rheum 2005. (in press)
3. The Wegener's Granulomatosis Etanercept Trial (WGET) Research Group. Etanercept plus standard therapy for Wegener's granulomatosis. N Engl J Med 2005; 352:351-361.
4. Jennette JC, Falk RJ, Andrassy K, et al. Nomenclature of systemic vasculitides: the proposal of an international consensus conference. Arthritis Rheum 1994;37:187-192.
5. Luqmani RA, Bacon PA, Moots RJ, et al. Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis. Q J Med 1994; 87:671-678.
6. de Groot K, Gross WL, Herlyn K, et al. Development and validation of a disease extent index for Wegener's granulomatosis. Clin Nephrol 2001; 55:31-38.
7. WGET Research Group. Design of the Wegener's Granulomatosis Etanercept Trial (WGET). Control Clin Trials 2002; 23:450-468.
8. Stone JH, Hoffman GS, Merkel PA, et al. A disease-specific activity index for Wegener's granulomatosis: modification of the Birmingham Vasculitis Activity Score. International Network for the Study of the Systemic Vasculitides (NYSSYS). Arthritis Rheum 2001; 44:912-920.